DEA Administrator Anne Milgram's statement on a potential mass fenanyl poisoning event in Gadsden County, Florida on July 2, 2022.

The DEA is seeing a nationwide spike in fentanyl-related mass-overdose events involving three or more overdoses occurring close in time at the same location. In just the past two months, there have been at least 7 confirmed mass overdose events across the United States resulting in 58 overdoses and 29...

DEA’s mission is to keep American communities safe and healthy and we are in the midst of an overdose crisis that has reached a devastating new height. 265 people die every day from drug overdoses. Countless more [people] overdose and are fortunate to survive. This is a national crisis. It...

Illicit stimulants, specifically cocaine and methamphetamine, remain a pervasive drug threat in Pennsylvania. PFD offices, state/local law enforcement agencies, and other stakeholders throughout Pennsylvania report persistent increases since 2017 in various indicators that demonstrate availability, such as the total quantity of illicit stimulants seized by law enforcement, identification of seized...

The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The Philadelphia Field Division (PFD) monitors this threat closely, periodically reviewing multiple data indicators, in conjunction with investigative information, to continually assess the threat, then share analytical findings with stakeholders in federal, state, and municipal governments.

Due to the efforts of DEA and our partners, from January 2017 through August 2020, we have seen the number of opioid prescriptions drop nearly 37 percent, a reduction in over 47 percent of opioids dispensed, and most importantly -- an 18 percent drop in prescription overdose deaths over the...

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) is advising law enforcement and public health counterparts of the increased availability of counterfeit controlled prescription drugs (CPDs) – commonly sold as legitimate CPDs with most containing fentanyl/ fentanyl-related compounds (FRC) – in Pennsylvania and Delaware.

The Drug Enforcement Administration (DEA) Heroin Signature Program (HSP) analyzes hundreds of wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels...

The HSP (Heroin Signature Program) is one essential component of the DEA’s Intelligence Program to identify trends in heroin trafficking and distribution in the United States. The objective of the program is to identify and quantify the chemical components of heroin seized at U.S. ports of entry (POE), all non-POE...